MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer
Conclusion:
This study highlights that acquisition of specific deregulated miRNAs is a newly discovered alternative mechanism developed by AI-resistant breast cancer cells to achieve constitutive activation of the AKT/mTOR pathway and develop AI resistance. It also highlights that miR-125b is a new biomarker of poor prognosis and a candidate therapeutic target of AI-resistant breast cancers.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Paul VilquinCaterina DoniniMarie VilledieuEvelyne GrisardLaura CorboThomas BachelotJulie VendrellPascale Cohen Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Genetics | Men | Menopause | Study